Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 16/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620561 | 0.84 | AAK1 (0.38) | CPB2CTSK | |
| SCHEMBL5705285 | 0.81 | CAPN1 (0.33) | — | |
| SCHEMBL4801806 | 0.79 | CAPN1 (0.46) | — | |
| SCHEMBL5705391 | 0.77 | CTSL (0.35) | CPB2CTSSCTSK | |
| SCHEMBL4622798 | 0.74 | CAPN1 (0.42) | — | |
| SCHEMBL4807068 | 0.73 | ARG1 (0.34) | — | |
| SCHEMBL7751628 | 0.73 | CPB2 (0.51) | CPB2CTSSCTSK | |
| SCHEMBL4806210 | 0.73 | CAPN1 (0.46) | — | |
| SCHEMBL3635784 | 0.73 | CAPN1 (0.39) | — | |
| SCHEMBL31433188 | 0.69 | CPB2 (0.51) | CPB2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465721-B2 | 2-hydroxytetrahydrofuran derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7384933-B2 | Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-06-10 | — | — | US | disclosed |
| EP-1701974-B1 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOD CONSEILS RECH APPLIC (FR) | 2008-03-26 | — | — | EP | disclosed |
| EP-1701974-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-09-20 | — | — | EP | disclosed |
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | disclosed |
| WO-2005056551-A2 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | CAPN2, CAPN1, CAPNS1 | CPB2 293/4885F2R 917/4885CYP3A4 1570/4885 |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | CAPN1, MYH10, CAPN9 | CPB2 1222/4885F2R 2618/4885CYP3A4 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.